Clinical Trial Update: Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial comparing exenatide with biphasic insulin aspart 30 for glucose variability in adults with type 2 diabetes has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)
• Insulin aspart 30, biphasic (insulin aspart 30)

Snippet

Sponsor: Xijing Hospital | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED